Amerge Articles
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
Stock Commentary - New York week to March 30, 2009
2 April 2009
Allergan reports strong 4th-qtr results
13 February 2006
Germany approves switch of a triptan
9 January 2006
Migraine prophylaxis drug market forecasts
15 November 2004
Elan's migraine drug nears US approval
4 May 2000
Schwarz Pharma profits fall 42%
16 February 2000
FDA requests drug interaction data for Pfizer's Relpax
26 October 1999
Maxalt outperforms rival triptans
1 July 1999
Vanguard Medica files Miguard NDA
2 February 1999
AstraZeneca's Effect On Rest Of Pharma Sector
17 December 1998
Evolution In Migraine Therapy; New Triptans, And Beyond
10 September 1998
MSD Launches Maxalt In The UK
9 September 1998
Merck's Maxalt Approved In USA
1 July 1998
Naratriptan Launched In The USA
26 March 1998
Vanguard Looks Back On Successful 1997
19 March 1998
Merck & Co's Rizatriptan Approved In Holland
25 February 1998
GW's Naratriptan Approved In The USA
12 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
Zeneca Upgraded By Goldman Sachs
27 January 1998
Migraine Market Hotting Up In The USA
20 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
US Approval For Zomig Tablets
4 December 1997
GW's Imitrex Approved In USA
4 September 1997
GW's Naramig Cleared In 10 European Markets
24 July 1997
New Migraine Drugs Featured At IHS Meeting
19 June 1997
First Launch For Naratriptan
19 May 1997
Investors Impressed With Glaxo Wellcome Pipeline
12 May 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
GW Licenses Migraine Drug To Zeneca
19 February 1996
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
Glaxo Wellcome Revamps R&D To Treble Productivity
13 November 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
EC Clears Glaxo's Wellcome Bid
6 March 1995
Glaxo Wellcome: Consolidatory But No Panacea
30 January 1995
Showing 1-47 of 47 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
